Unmet Needs in Bispecific Therapy Access

EP: 1.Bispecific Antibodies in DLBCL: Therapeutic Potential

EP: 2.Efficacy Insights on Bispecific Antibodies in DLBCL

EP: 3.Bispecific Antibodies in DLBCL Trials

EP: 4.Bispecific Antibodies in DLBCL: Patient Response

EP: 5.Future Insights on Bispecific Therapies

EP: 6.Overcoming DLBCL Treatment Hurdles

EP: 7.Patient Education and Monitoring in DLBCL Treatment

EP: 8.Implementing Bispecific Treatments

EP: 9.Bispecific Toxicity Management in DLBCL Care

EP: 10.Multidisciplinary Bispecific Care

EP: 11.Pharmacists: Bispecifics and Operational Role

EP: 12.Strategies for Reducing Bispecific Therapy Toxicities

Now Viewing

EP: 13.Unmet Needs in Bispecific Therapy Access

EP: 14.Implementing Bispecific Antibodies in Lymphoma Care

This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.

In this segment, Mahmoudjafari and Ali discuss the unmet needs and educational aspects related to the use of bispecifics in community oncology. Ali emphasizes the growing significance of bispecifics in treatment algorithms and encourages community oncology partners to embrace and learn to manage these agents effectively. He highlights the importance of collaboration between community and academic centers to ensure patients can access these therapies locally. Mahmoudjafari underscores the need for further education, particularly in enhancing comfort levels with bispecifics, acknowledging that education alone may not alleviate concerns. Mancini emphasizes the importance of practical experience to build comfort with bispecifics, breaking down adverse effects to demystify concerns. The speakers stress the necessity of fostering access, comfort, and understanding among health care providers to optimize the use of bispecific antibodies in community settings.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.